Study guide
5.1 Routine Prenatal Care, Screening & Fetal Assessment
Saudi Medical Licensing Examination SMLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview & Foundation of Clinical Practice
1.1 Exam Format, Blueprint & Preparation Strategy 1.2 Medical Bioethics, Patient Safety & SCFHS Regulations 1.3 Biostatistics & Clinical Epidemiology in Saudi Healthcare
2 Chapter 2: Internal Medicine - Cardiovascular & Respiratory Systems
2.1 Coronary Artery Disease, Dysrhythmias & Heart Failure 2.2 Respiratory Failure, Asthma, COPD & Infiltrative Lung Diseases 2.3 Critical Care Medicine, Shock Syndromes & Mechanical Ventilation
3 Chapter 3: Internal Medicine - Gastroenterology, Renal & Endocrine Systems
3.1 Hepatobiliary Disorders, Peptic Ulcers & Inflammatory Bowel Disease 3.2 Acute Kidney Injury, Chronic Kidney Disease & Electrolyte Imbalances 3.3 Diabetes Mellitus, Thyroid Disorders & Adrenal Axis Pathologies
4 Chapter 4: Internal Medicine - Infectious Diseases, Hematology & Subspecialties
4.1 Saudi Regional Infections (MERS-CoV, Brucellosis, TB, Dengue) & Antimicrobial Therapy 4.2 Hemoglobinopathies (Sickle Cell & Thalassemia), Anemias & Hematologic Malignancies 4.3 Connective Tissue Diseases, Stroke, Epilepsy & Movement Disorders 4.4 Psychiatry, Geriatrics & Behavioral Health
5 Chapter 5: Obstetrics - Antepartum & Intrapartum Care
5.1 Routine Prenatal Care, Screening & Fetal Assessment 5.2 Placental Disorders, Bleeding in Pregnancy & Isoimmunization 5.3 Normal Labor, Malpresentation, Operative Delivery & Fetal Monitoring
6 Chapter 6: Obstetrics - High-Risk Complications & Postpartum Care
6.1 Preeclampsia, Eclampsia & HELLP Syndrome 6.2 Preterm Labor, Premature Rupture of Membranes & Cervical Insufficiency 6.3 Postpartum Hemorrhage, Puerperal Infections & Maternal Mortality
7 Chapter 7: Gynecology & Reproductive Health
7.1 Menstrual Disorders, Endometriosis & Fibroids 7.2 Infertility Workup, Contraception & Menopause 7.3 Cervical, Uterine & Ovarian Neoplasms
8 Chapter 8: General Pediatrics, Neonatology & Development
8.1 Developmental Milestones, Growth Charts & Failure to Thrive 8.2 Saudi National Immunization Schedule & Well-Child Care 8.3 Neonatal Resuscitation, Jaundice, Respiratory Distress & Prematurity
9 Chapter 9: Pediatric Medicine - Respiratory, Cardiac & GI
9.1 Croup, Epiglottitis, Bronchiolitis, Asthma & Cystic Fibrosis 9.2 Congenital Heart Disease (Cyanotic & Acyanotic) & Rheumatic Fever 9.3 Dehydration, Gastroenteritis, Intussusception & Pyloric Stenosis
10 Chapter 10: Pediatric Medicine - Infections, Hematology, Emergencies & Subspecialty Systems
10.1 Exanthems, Meningitis, Sepsis & Febrile Seizures 10.2 Pediatric Sickle Cell Vaso-occlusive Crises, Thalassemia & ITP 10.3 Pediatric Trauma, Ingestion, Poisoning & Child Abuse Recognition 10.4 Pediatric Neurology, Nephrology & Musculoskeletal Disorders
11 Chapter 11: General Surgery & Surgical Principles
11.1 Preoperative Risk Assessment, Wound Healing & Surgical Infections 11.2 Fluid Resuscitation, Acid-Base Disturbances & Surgical Shock 11.3 Acute Abdomen, Appendicitis, Hernias, Gallbladder & Colorectal Surgery
12 Chapter 12: Trauma, Critical Care & Surgical Emergencies
12.1 ATLS Primary/Secondary Survey, Thoracic & Abdominal Trauma 12.2 Thermal/Chemical Burns, Parkland Formula & Wound Management 12.3 Breast Masses, Thyroid Nodule Evaluation & Surgical Oncology
13 Chapter 13: Surgical Subspecialties
13.1 Nephrolithiasis, BPH, Prostate Cancer & Increased Intracranial Pressure 13.2 Common Fractures, Compartment Syndrome & Pediatric Orthopedics 13.3 Epistaxis, Red Eye Emergencies, Peripheral Vascular Disease & Aortic Aneurysms
5.1 Routine Prenatal Care, Screening & Fetal Assessment
Key Takeaways Explain This Topic AI
First-trimester ultrasound measurement of the crown-rump length is the most accurate method for establishing the estimated date of delivery.
Routine universal screening for Gestational Diabetes Mellitus (GDM) is performed at 24-28 weeks using a 50g 1-hour glucose challenge test.
Group B Streptococcus (GBS) screening should be performed at 36-37 weeks of gestation; positive results require intrapartum penicillin prophylaxis.
A reactive Non-Stress Test (NST) requires at least two fetal heart rate accelerations of 15 bpm lasting 15 seconds within a 20-minute window.
The Biophysical Profile (BPP) utilizes ultrasound and NST to evaluate fetal well-being; a score of 8/10 or 10/10 is reassuring.
Last updated: July 2026
Introduction to Routine Prenatal Care
Routine prenatal care is a cornerstone of obstetrics, designed to optimize maternal and fetal outcomes by identifying and mitigating risks early in gestation. A structured schedule of prenatal visits ensures timely screening, monitoring, and educational interventions. For uncomplicated pregnancies, the standard visit frequency is every 4 weeks until 28 weeks of gestation, every 2 weeks from 28 to 36 weeks, and weekly from 36 weeks until delivery.
The First Prenatal Visit
The initial visit, ideally occurring in the first trimester, involves a comprehensive medical, surgical, family, and obstetric history. Accurate determination of gestational age and the estimated date of delivery (EDD) is critical. While Naegele's rule (subtract 3 months and add 7 days to the first day of the Last Menstrual Period) provides a clinical estimate, first-trimester ultrasound measurement of the crown-rump length (CRL) is the most accurate method for dating a pregnancy and should be used to confirm or establish the EDD.
Routine laboratory investigations at the first visit include:
Complete Blood Count (CBC): To screen for baseline anemia and thrombocytopenia.
Blood Type, Rh factor, and Antibody Screen: Essential for identifying risk of isoimmunization.
Infectious Disease Screening: Rubella IgG, Syphilis (VDRL/RPR), HIV, Hepatitis B surface antigen (HBsAg), and Chlamydia PCR. Gonorrhea testing is risk-based but commonly included.
Urinalysis and Urine Culture: To detect asymptomatic bacteriuria, which carries a high risk of progression to pyelonephritis in pregnancy.
Aneuploidy Screening
Screening for fetal chromosomal abnormalities is offered to all pregnant women, regardless of age, though advanced maternal age (>35 years) significantly increases risk.
Screening Modality Timing Components Findings in Trisomy 21 (Down Syndrome)
First-Trimester Combined 11-13 weeks Ultrasound nuchal translucency (NT), serum PAPP-A, beta-hCG Increased NT, Decreased PAPP-A, Increased beta-hCG
Cell-Free DNA (NIPT) >10 weeks Maternal serum testing for fetal DNA fragments Highly sensitive (>99%) and specific for T21, T18, T13
Quadruple Screen 15-20 weeks AFP, beta-hCG, Estriol, Inhibin A Decreased AFP, Increased beta-hCG, Decreased Estriol, Increased Inhibin A
It is important to note that an elevated maternal serum alpha-fetoprotein (MSAFP) alone is strongly associated with neural tube defects (e.g., spina bifida, anencephaly) or abdominal wall defects, rather than aneuploidy.
Second and Third Trimester Screening
Gestational Diabetes Mellitus (GDM) Screening: Universal screening is performed at 24 to 28 weeks. The two-step approach is most common: an initial 50g 1-hour glucose challenge test (GCT). If the 1-hour value is elevated (typically >135 or 140 mg/dL), a confirmatory 100g 3-hour oral glucose tolerance test (OGTT) is performed. Diagnosis requires two or more elevated values on the OGTT (Fasting >95, 1h >180, 2h >155, 3h >140 mg/dL).
Anemia Screening: A repeat CBC is drawn at 24-28 weeks. Dilutional anemia of pregnancy is common, but hemoglobin <11 g/dL in the first/third trimesters or <10.5 g/dL in the second trimester requires investigation and iron supplementation.
Group B Streptococcus (GBS) Screening: A rectovaginal swab is collected at 36 to 37 weeks. GBS is a leading cause of neonatal sepsis. If positive, or in cases of GBS bacteriuria during the current pregnancy or a previous infant with invasive GBS disease, the mother must receive intrapartum intravenous antibiotic prophylaxis (Penicillin G is first-line).
Fetal Assessment and Surveillance
Fetal well-being surveillance is indicated for high-risk pregnancies (e.g., preeclampsia, IUGR, GDM, post-term) to detect fetal hypoxia and prevent stillbirth. Assessment begins with maternal perception of fetal movement (kick counts); a normal finding is 10 movements within 2 hours.
Non-Stress Test (NST): Evaluates fetal heart rate (FHR) accelerations in response to fetal movement, reflecting a healthy autonomic nervous system. A reactive (reassuring) NST in a pregnancy >32 weeks requires at least 2 FHR accelerations of 15 bpm above baseline, lasting 15 seconds, within a 20-minute window.
Biophysical Profile (BPP): Combines an NST with a targeted ultrasound assessing four additional parameters (amniotic fluid volume, fetal breathing, fetal movement, and fetal tone). Each parameter scores 2 if reassuring, 0 if non-reassuring. A total score of 8/10 or 10/10 is normal; 6/10 is equivocal (may require repeat or delivery depending on gestational age); 4/10 or less indicates severe fetal compromise mandating prompt delivery.
Umbilical Artery Doppler Velocimetry: Used primarily in the management of fetal growth restriction (FGR/IUGR). It assesses placental vascular resistance. Absent or reversed end-diastolic flow is an ominous sign of impending fetal hypoxia and often prompts immediate delivery.